Remove topics healthcare-reform
article thumbnail

New CCC Study Finds Executives Create Greatest Risk for Copyright Infringement

Velocity of Content

From Research and Industry News to Workforce Trends and Legislative Reform, Organizations Rely on the Reuse of Published Content to Support Collaboration and Drive Innovation CCC today announced key findings from the just released “ Information Seeking and Consumption Study ” based on data gathered by Outsell, Inc.,

article thumbnail

Obituary - Professor Margaret Sophia Moy Llewelyn (1962-2021)

The IPKat

Following discussions with Bill Cornish, our topic of ‘law and genetics’ was narrowed to ‘law and human genetics’; and, with Bill’s encouragement, a number of exploratory papers were presented at a workshop in Cambridge, leading to a special issue of the Modern Law Review which was then re-published by Hart. Always a pleasure and stimulating.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

SpicyIP Weekly Review (July 5-11)

SpicyIP

Topical Highlight. After the Tribunal Reforms (Rationalisation and Conditions of Service) Ordinance 2021, disbanded the IPAB and transferred its powers to the High Courts and Commercial Courts, the IPD has been constituted on the basis of the recommendations of a two-member committee consisting of Justice Prathiba M. Other Posts.

article thumbnail

WHAT, IN THE NAME OF GOD, …?: Intellectual Property Rights In Holy Names, Sacred Words, & Other Aspects of Creation

LexBlog IP

It is closely related to the Reformed doctrine of justification by grace through faith alone. It can also mean as the proxy or substitute holder of rights here on earth because no spiritual being will receive a copyright certificate, trademark registrations, or letters patent.

article thumbnail

Biosimilars 2021 Year in Review

Fish & Richardson Trademark & Copyright Thoughts

The letter discusses the BPCIA and the Hatch-Waxman Act frameworks (for small molecule drugs) and sets forth several topics for USPTO’s consideration and further discussion: engagement between FDA and USPTO to increase efficiencies, possible misuse of the patent system (e.g.,